Back to Authors

Dodick, David W.

https://orcid.org/0000-0002-9486-6790

A5057290642 | I1330342723

Mayo Clinic

Atria Academy of Science and Medicine, New York, NY, United States

Citations 387

Randomized, Double-blind, Placebo-controlled Trial of ALD403, an anti-CGRP peptide antibody in the prevention of chronic migraine. (S52.003)

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.s52.003

75% responder rates provide improvement in HIT-6 scores from week 4 through 12 following a single infusion of ALD403, or placebo. (P2.165)

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.p2.165

A Brief Survey on Academic Headache Centers Knowledge of and Interest in ACGME recognition of Headache Medicine Fellowships (P1.203)

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.p1.203

Real World Efficacy, Tolerability and Safety of Ubrogepant (2485)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2485

Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study (2328)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2328

Impact of Abuse on Migraine Symptoms and Comorbidity: Results from the American Registry for Migraine Research (ARMR) (2187)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2187

Risk of Hypertension in Erenumab-treated Patients With Migraine in Clinical Trials and in the Postmarketing Setting (2168)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2168

Use of Medical Education Program to Identify Practice Gaps Among Neurologists in the Use of Preventive Therapies for the Management of Migraine (1879)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1879

Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT Analysis (1841)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1841

Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine (1459)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1459